Camille E Introcaso1, Eileen F Dunne1, Susan Hariri1, Gitika Panicker2, Elizabeth R Unger2, Lauri E Markowitz1. 1. Division of Sexually Transmitted Disease Prevention, National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: A vaccine is available to prevent human papillomavirus (HPV) 6, 11, 16 and 18; in the prevaccine era, seropositivity to vaccine types is a measure of natural exposure. METHODS: We describe HPV seropositivity in the USA among 14-59-year-olds using the 2003-2006 National Health and Nutrition Examination Surveys. RESULTS: Seropositivity to HPV 6, 11, 16 and 18 was 17.5%, 6.8%, 15.1% and 5.9%, respectively, among women, and 7.0%, 2.4%, 5.2% and 1.5%, respectively, among men. Overall in both sexes, seropositivity was 22.5% for any vaccine type (31.8% in women and 12.9% in men), but substantially lower for three or more types (1.7% overall, 2.8% in women and 0.6% in men). CONCLUSIONS: Almost a quarter of the participants were seropositive to any HPV vaccine type but few were seropositive to at least three vaccine HPV types in the prevaccine era. Further study is needed to assess if seropositivity would be useful as a biological marker of vaccination. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: A vaccine is available to prevent human papillomavirus (HPV) 6, 11, 16 and 18; in the prevaccine era, seropositivity to vaccine types is a measure of natural exposure. METHODS: We describe HPV seropositivity in the USA among 14-59-year-olds using the 2003-2006 National Health and Nutrition Examination Surveys. RESULTS: Seropositivity to HPV 6, 11, 16 and 18 was 17.5%, 6.8%, 15.1% and 5.9%, respectively, among women, and 7.0%, 2.4%, 5.2% and 1.5%, respectively, among men. Overall in both sexes, seropositivity was 22.5% for any vaccine type (31.8% in women and 12.9% in men), but substantially lower for three or more types (1.7% overall, 2.8% in women and 0.6% in men). CONCLUSIONS: Almost a quarter of the participants were seropositive to any HPV vaccine type but few were seropositive to at least three vaccine HPV types in the prevaccine era. Further study is needed to assess if seropositivity would be useful as a biological marker of vaccination. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer Journal: Sex Transm Dis Date: 2016-03 Impact factor: 2.830
Authors: Rachel A Katzenellenbogen; Joseph J Carter; Joshua E Stern; Melinda S Butsch Kovacic; Parinda A Mehta; Sharon L Sauter; Denise A Galloway; Rachel L Winer Journal: Clin Vaccine Immunol Date: 2015-02-04
Authors: Elissa Meites; Pamina M Gorbach; Beau Gratzer; Gitika Panicker; Martin Steinau; Tom Collins; Adam Parrish; Cody Randel; Mark McGrath; Steven Carrasco; Janell Moore; Akbar Zaidi; Jim Braxton; Peter R Kerndt; Elizabeth R Unger; Richard A Crosby; Lauri E Markowitz Journal: J Infect Dis Date: 2016-06-13 Impact factor: 5.226
Authors: Carlos R Oliveira; Robert M Rock; Eugene D Shapiro; Xiao Xu; Lisbet Lundsberg; Liye B Zhang; Aileen Gariepy; Jessica L Illuzzi; Sangini S Sheth Journal: Am J Obstet Gynecol Date: 2017-12-06 Impact factor: 10.693
Authors: Emiko Y Petrosky; Susan Hariri; Lauri E Markowitz; Gitika Panicker; Elizabeth R Unger; Eileen F Dunne Journal: Int J Infect Dis Date: 2015-01-14 Impact factor: 3.623
Authors: Shams Rahman; Christine M Pierce Campbell; Dana E Rollison; Wei Wang; Tim Waterboer; Angelika Michel; Michael Pawlita; Luisa L Villa; Eduardo Lazcano Ponce; Amy R Borenstein; Anna R Giuliano Journal: PLoS One Date: 2016-11-30 Impact factor: 3.240
Authors: Jeannette Y Lee; Ishwori Dhakal; Corey Casper; Ariela Noy; Joel M Palefsky; Missak Haigentz; Susan E Krown; Richard F Ambinder; Ronald T Mitsuyasu Journal: J Cancer Epidemiol Date: 2016-11-02
Authors: A P Ortiz; G Tortolero-Luna; J Romaguera; C M Pérez; D González; C Muñoz; L González; E Marrero; E Suárez; J M Palefsky; G Panicker; E R Unger Journal: Papillomavirus Res Date: 2018-03-16